Novelogics Biotechnology Inc. is a pre-clinical stage biotech company specializing in the development of innovative antibody immunotherapies for cancer. The company operates in the oncology sector, targeting the growing market for cancer treatments, which is projected to generate $111 billion annually by 2020. Novelogics aims to address the shortcomings of current cancer treatments, which often make patients sick before they can get better. By leveraging a novel approach to immunotherapy, the company seeks to provide safer and more effective treatment options.

Novelogics primarily serves pharmaceutical companies that are actively seeking early-stage drugs with unique mechanisms of action (MOA) for standalone or combination therapies. The company’s business model involves seeking staged investments and partnerships to advance its program. Revenue generation is anticipated through licensing agreements, milestone payments, and eventual product sales once clinical trials are successfully completed and regulatory approvals are obtained.

The company has garnered recognition for its innovative solutions, winning awards such as the 'Innovative' award at the Angel Forum in April 2019 and the 'Pre-Revenue' award at the 44th edition of the Angel Forum Vancouver, presented by PwC in November 2018. These accolades underscore the company's potential and the interest it has generated within the investment community.

Key team members include Co-Founder Dr. Wayne Cheney, who brings over 28 years of combined research and development experience, with a significant focus on oncology. His expertise is instrumental in driving the company's mission to revolutionize cancer treatment.

Keywords: antibody immunotherapies, cancer treatment, oncology, pre-clinical stage, biotechnology, innovative solutions, pharmaceutical partnerships, investment, safety, efficacy.